Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2024 | Story André Damons | Photo Suplied
Dr Claudia Ntsapi
Dr Matlakala C Ntsapi is a Senior Lecturer and researcher in the Department of Basic Medical Sciences at the UFS.

A researcher from the University of the Free State (UFS) is investigating the potential benefits of medicinal plants as supplementary treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

The work of Dr Matlakala Claudia Ntsapi, Senior Lecturer in the Department of Basic Medical Sciences at the UFS, focuses on preserving human brain health to delay or prevent age-related conditions.

According to her, while the primary focus is on age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, the bioactive compounds in these medicinal plants may also have therapeutic potential for other neurological disorders, various types of cancers and Type 2 Diabetes. The broad protective effects of these plant-based bioactive compounds could make them relevant in the potential treatment of other diseases involving oxidative stress and inflammation.

She is involved in several multidisciplinary projects, collaborating with research experts from Denmark, the UK, and various national institutions such as the Central University of Technology (CUT), North West University (NWU), and the Stellenbosch University (SUN), as well as colleagues from the UFS. 

The potential of medicinal plants

“In collaboration with experts from our institution, the CUT and SU, who have strong backgrounds in pharmacology and ethnobotany, we are focusing on underexplored medicinal plants and nutraceuticals. These plants contain bioactive compounds with potential neuroprotective properties, which are believed to provide extra health benefits beyond basic nutritional value,” says Dr Ntsapi.

“We hope that these medicinal plants have the potential to preserve cognitive function and slow the progression of neurodegenerative diseases like Alzheimer’s. Specifically, we aim to identify novel therapeutic targets and discover new avenues for intervention that can improve the quality of life for individuals affected by age-related brain conditions,” she says.

Identifying therapeutic targets and discovering new interventions

The bioactive compounds found in selective medicinal plants and nutraceuticals, explains Dr Ntsapi, serve as a promising source of ‘natural’ therapeutics that may be safer and have fewer side effects compared to conventional synthetic drugs. Additionally, the untapped potential of these compounds for neuroprotection and the preservation of brain health could provide innovative therapeutic solutions. These compounds may be used as complementary therapies to existing drugs, which often have limited efficacy on their own, thereby enhancing overall treatment outcomes for neurodegenerative diseases.

“By utilising cutting-edge techniques, such the innovative CelVivo ClinoStar 2 System, we strive to gain insights into the safety and efficacy of underexplored medicinal plants in preserving cognitive function and slowing disease progression.

“By exploring the untapped potential of bioactive compounds found in medicinal plants and nutraceuticals, our research group aims to contribute to the identification of novel therapeutic targets and the discovery of new avenues for intervention to improve the quality of life for individuals affected by age-related brain conditions,” says Dr Ntsapi.

The researchers, in collaboration with others in the UFS School of Clinical Medicine, will develop 3D cell-based models of the human cortex and hippocampus by utilising the CelVivo ClinoStar 2 System. This cutting-edge technology, housed in an easy-to-use CO² incubator, mimics ‘animal model-like’ conditions with low sheer stress, allowing scientists to generate cell-based models that closely resemble real-world conditions.

Dr Ntsapi explains that they will specifically focus on the technologies’ applications in studying age-related neurodegenerative disorders, such as Alzheimer’s disease. The potential impact of this research is immense, as it could contribute to the development of novel therapeutic strategies for combating the debilitating progression of neurodegenerative diseases, and ultimately improving the quality of life for affected individuals.

Hope for the research

“Our hope for this research is to significantly advance our understanding of neurodegenerative disease progression and to develop novel therapeutic strategies that can effectively combat these debilitating conditions. Ultimately, we aim to improve the quality of life for individuals affected by neurodegenerative diseases by preserving cognitive function and slowing disease progression.

“This research will contribute to the knowledge pool in this field, with the potential to lead to groundbreaking discoveries in the treatment of Alzheimer’s disease and other related disorders, potentially contributing to the policy guidelines on how these conditions are managed and treated,” she says.

The international partners from Denmark and the UK have made their expertise and facilities available to postgraduate students from the UFS, some of whom they are co-supervising.

Dr Ntsapi, who is passionate about exploring innovative solutions to address the gradual decline in normal brain function associated with aging, was this year one the university’s nominations for the prestigious 2023/2024 NSTF-South32 Awards, popularly known as the “Science Oscars” of South Africa. 

News Archive

UFS awards honorary degree to Justice Richard Goldstone
2012-01-26

 
Justice Richard Goldstone

A huge honour will be bestowed upon the University of the Free State (UFS) when the world renowned Justice Richard Goldstone will be receiving an honorary degree at the official opening of our university.

The Doctor of Laws (honoris causa) degree will be conferred on Justice Goldstone on Friday 3 February 2012 at 10:00 on our Bloemfontein Campus.

Mr Richard Freedman, Director of the South African Holocaust and Genocide Foundation, and Judge Mahube Molemela, Justice of the Free State High Court, are amongst the prominent figures expected to attend this event.

Justice Goldstone served in the Constitutional Court from 1995 to 2003. Prior to that, he was a judge of the High Court and from 1989 a judge of the Supreme Court of Appeal. From 1994 to 1996 he was the first Chief Prosecutor of the United Nations Criminal Tribunals for the former Yugoslavia and Rwanda. He is presently a Senior Fellow at the Jackson Institute at Yale University in the United States. Over the past 18 years he has become a leading expert on international criminal law.

Prof. Neels Swanepoel, Head of the Department of Law of Procedure and Law of Evidence, said the faculty is proud to honour Judge Richard Goldstone for his outstanding legal career and in particular for his contribution to the development of international criminal justice.

“As Chief Prosecutor for both the International Criminal Tribunal for the former Yugoslavia (ICTY) as well as the International Criminal Tribunal for Rwanda (ICTR), he has contributed to precedent-setting judgments on genocide, war crimes and crimes against humanity. His publications on various aspects of International Criminal Justice have contributed towards the stage where those bearing the greatest responsibility for human and humanitarian rights violations, will face justice.”

Prof. Swanepoel says judge Goldstone has contributed towards laying the foundations for conflict resolution in societies that have transformed from repressive to democratic rule and to what is now referred to as ‘transitional justice’.

On Thursday 2 February 2012 at 19:00, Judge Goldstone will deliver a Prestige Lecture on ‘The Future of International Criminal Justice’ in the Auditorium of the C.R Swart Building on the UFS Bloemfontein Campus.

 

Media Release
26 January 2012
Issued by: Lacea Loader
Director: Strategic Communication
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept